Clinical Trial Update: Margetuximab Expanded Access Program

View source ↗

Summary

Margetuximab has received marketing approval, advancing its expanded access program for HER2-positive breast cancer and other HER2-positive carcinomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Carcinoma

Drugs mentioned

• Margetuximab (margetuximab)

Snippet

Sponsor: TerSera Therapeutics LLC | Conditions: HER2-positive Breast Cancer, HER2-positive Carcinoma | Status: APPROVED_FOR_MARKETING